Clinical Trials Logo
  1. Home
  2. Alagille Syndrome
  3. NCT04674761

Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome — ASSERT  

Alagille Syndrome Clinical Trial

Official title:
A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT)

Clinical Trial Summary

Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in Patients with Alagille Syndrome.

Clinical Trial Description

Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04674761
Study type Interventional
Source Ipsen
Contact
Status Completed
Phase Phase 3
Start date March 19, 2021
Completion date September 9, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04729751 - A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). Phase 2
Active, not recruiting NCT05035030 - Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome Phase 3
Recruiting NCT06193928 - Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome (LEAP)
Completed NCT02160782 - Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) Phase 2
Completed NCT00007033 - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease N/A
Suspended NCT00571272 - Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
Completed NCT02057692 - Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome Phase 2
Active, not recruiting NCT02922751 - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Completed NCT00001642 - Positional Cloning of the Gene(s) Responsible for Alagille Syndrome N/A
Recruiting NCT05488067 - Atorvastatin Therapy on Xanthoma in Alagille Syndrome Phase 4
Completed NCT02117713 - An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome Phase 2
Completed NCT02131623 - Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
Completed NCT02963077 - A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 Phase 1
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT03082937 - An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects Phase 1
Completed NCT02047318 - An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) Phase 2
Completed NCT01903460 - Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome Phase 2
Completed NCT01515631 - Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review
Enrolling by invitation NCT05846854 - Decreasing Hemorrhage Risk in Children With Alagille Syndrome N/A
Approved for marketing NCT04530994 - A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)